Company intelligence / Profile preview

KalvoTech

Southsea, England, United Kingdomkalvotech.com ↗

Ownership: Private
Development stage: Other

Overview

KalvoTech has developed Prokitein™, a proprietary protein-based biopolymer platform designed to enhance cell cultivation and bioprocessing. Their edible hollow fibre membranes mimic vascular systems in bioreactors, improving nutrient delivery and cell growth for applications such as cultivated meat. The company is focused on R&D and has expanded its facilities since its founding in 2023.

Therapeutic areas: Other
Modalities: Biomaterial (protein-based biopolymer)Device (edible hollow fibre membranes for bioreactors)
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on KalvoTech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KalvoTech.

Explore the full profile